NASDAQ$APGE

Apogee Therapeutics Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Headline financials

EPS (adj)

-$3.78

Previous: -$5.25+28.0%
Net Income

-$18.9M

Previous: -$1.82M-939.9%
Operating Income

-$18.9M

Previous: -$1.82M-939.9%
Cash & Equivalents

$125M

Previous: $4.97M+2414.5%
Total Assets

$131M

No prior period
Stock-Based Comp

$1.11M

Previous: $1.7M-34.5%

Revenue & EPS history

Apogee · Revenue · Quarterly

$0

Q4 2025

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 15 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

+5.6%

Avg return

Earnings day

+9.2%

Avg return

5 days after

+10.9%

Avg return

30 days after

53%

8 / 15 earnings

Positive

+59.8%

Q4 2023

Best reaction

-12.7%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+1.2%+4.4%+20.3%
Q3 2025+3.8%+19.7%+39.0%
Q2 2025-2.2%+5.4%+5.9%
Q1 2025-0.0%-1.1%+9.4%
Q4 2024-0.2%+14.9%+20.3%
Q3 2024-12.7%-21.8%-26.7%
Q2 2024+9.7%+11.7%+25.0%
Q1 2023+1.5%-5.5%-16.7%
Q1 2024+1.5%-5.5%-16.7%
Q4 2023+59.8%+61.8%+41.4%
Q3 2023+12.8%+20.6%+45.9%
Q3 2022+12.8%+20.6%+45.9%
Q4 2022-1.1%+4.0%-9.6%
Q2 2022-1.1%+4.0%-9.6%
Q2 2023-1.1%+4.0%-9.6%
Q1 2022

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro